Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

941
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
941
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

674
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
674
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

951
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
951
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

343
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
343
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.1K
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

1.0K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality.

Cancer·2026
Same author

Fluoropyrimidine Cardiotoxicity: Role of Uridine Triacetate and Pharmacogenomic Insights from a Case of 5-FU-Induced Cardiogenic Shock.

Journal of cardiovascular pharmacology·2026
Same author

Current Perspectives in Cardio-oncology: Insights from Global Experts.

European cardiology·2026
Same author

Sacubitril/Valsartan in Anthracycline-Treated Patients: A Systematic Review and Meta-Analysis of Available Evidence.

JACC. CardioOncology·2026
Same author

Expanding the Therapeutic Landscape of Pericarditis: A Systematic Review of the Use of Conventional Immunosuppressants.

Medicina (Kaunas, Lithuania)·2026
Same author

Updates on Pathophysiology of Pericarditis to Guide Development of Therapeutics.

Current cardiology reports·2026

Related Experiment Video

Updated: Nov 26, 2025

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level
07:28

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level

Published on: January 24, 2025

565

In ®Entresto we trust.

Massimiliano Camilli1, Marco Giuseppe Del Buono1, Pierantonio Menna2

  • 1Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy.

Cardio-Oncology (London, England)
|December 9, 2020
PubMed
Summary
This summary is machine-generated.

Sacubitril/Valsartan effectively treats heart failure with reduced ejection fraction (HFrEF). This study suggests its potential benefit in cancer patients with therapy-induced HFrEF, a group previously excluded from trials.

Keywords:
Cardio-oncologyHeart failureSacubitril/valsartan

More Related Videos

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.2K
Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model
05:09

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Published on: April 28, 2023

1.2K

Related Experiment Videos

Last Updated: Nov 26, 2025

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level
07:28

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level

Published on: January 24, 2025

565
Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.2K
Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model
05:09

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Published on: April 28, 2023

1.2K

Area of Science:

  • Cardio-Oncology
  • Pharmacology
  • Heart Failure Management

Background:

  • Heart failure with reduced ejection fraction (HFrEF) is a significant concern in cancer patients.
  • Cancer therapies, such as anthracyclines, can induce cardiotoxicity leading to HFrEF.
  • Patients with cancer therapy-induced HFrEF were excluded from pivotal Sacubitril/Valsartan trials.

Purpose of the Study:

  • To evaluate the efficacy and safety of Sacubitril/Valsartan (S/V) in patients with HFrEF caused by cancer therapy.
  • To establish the value of S/V in this specific, vulnerable patient subgroup.

Main Methods:

  • Retrospective analysis of a small cohort of cancer patients with HFrEF.
  • Patients primarily included women with breast cancer treated with anthracyclines.
  • Assessment of S/V treatment effects on cardiac function and clinical outcomes.

Main Results:

  • Limited data suggest Sacubitril/Valsartan shows encouraging effects in this population.
  • Results appear consistent with prior studies on S/V in broader HFrEF populations.
  • No major adverse events related to S/V were highlighted in this small group.

Conclusions:

  • Sacubitril/Valsartan may be a valuable treatment option for cancer patients with therapy-induced HFrEF.
  • Further prospective studies are warranted to confirm these preliminary findings.
  • This research supports the consideration of S/V in cardio-oncology practice.